Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model

Jeanine M. Walenga, Michael J. Koza, Soon J. Park, Mark R. Terrell, Roque Pifarré

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recombinant desulphatohirudin HV1 (CGP 39393), a specific and potent peptidic inhibitor of thrombin, was evaluated as the sole anticoagulant in a dog model of cardiopulmonary bypass. CGP 39393 was administered as a bolus plus infusion for a 1-hour pump period at doses of 1.0 mg/kg + 0.75 mg·kg-1.h-1, 1.0 mg/kg + 1.50 mg · kg-1 · h-1, 1.0 mg/kg + 225 mg · kg-1 · h-1, or 1.0 mg/kg + 3.0 mg · kg-1 · h-1 (n = 5 per group). The lowest dose was ineffective, as a high degree of clot formation (314 ± 160 mg) occurred as determined by quantitation of protein deposits in the pump line filter. The three higher doses inhibited clot formation (35 to 44 mg) but did not reveal a dose-dependent effect (p = 0.308 between groups). All four doses produced the same amount of postoperative blood loss (6.5 to 10 g/kg over 2 hours; p = 0.215 between groups) and no oozing of blood from cut tissues (sternum, muscle, skin) during or after operation. No adverse hemodynamic or hematologie effeds were observed. Animals were physiologically stable coming off pump, requiring minimal fluid replacement or other cardiovascular supportive measures. The chromogenic anti-lla assay could be used to monitor CGP 39393. Same activated partial thromboplastin time and all activated clotting time values were off scale on pump, but they fell immediately after cardiopulmonary bypass, typicalty reaching near-normal levels within 30 to 60 minutes. No reversal of CGP 39393 was used, as blood levels declined rapidly after cessation of the infusion. This stady in 2 dog model shows that CGP 39393 administered as a bolus plus infusion (minimum dose, 1.0 mg/kg + 1.50 mg · kg-1 · h-1) can be used safely and effectively during cardiopulmonary bypass for cardiac operation.

Original languageEnglish (US)
Pages (from-to)1685-1689
Number of pages5
JournalThe Annals of Thoracic Surgery
Volume58
Issue number6
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Anticoagulants
Dogs
Postoperative Hemorrhage
Sternum
Partial Thromboplastin Time
Thrombin
desirudin
Hemodynamics
Muscles
Skin
Proteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model. / Walenga, Jeanine M.; Koza, Michael J.; Park, Soon J.; Terrell, Mark R.; Pifarré, Roque.

In: The Annals of Thoracic Surgery, Vol. 58, No. 6, 1994, p. 1685-1689.

Research output: Contribution to journalArticle

Walenga, Jeanine M. ; Koza, Michael J. ; Park, Soon J. ; Terrell, Mark R. ; Pifarré, Roque. / Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model. In: The Annals of Thoracic Surgery. 1994 ; Vol. 58, No. 6. pp. 1685-1689.
@article{e22b650609bc4b6494392b6b2d6e869c,
title = "Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model",
abstract = "Recombinant desulphatohirudin HV1 (CGP 39393), a specific and potent peptidic inhibitor of thrombin, was evaluated as the sole anticoagulant in a dog model of cardiopulmonary bypass. CGP 39393 was administered as a bolus plus infusion for a 1-hour pump period at doses of 1.0 mg/kg + 0.75 mg·kg-1.h-1, 1.0 mg/kg + 1.50 mg · kg-1 · h-1, 1.0 mg/kg + 225 mg · kg-1 · h-1, or 1.0 mg/kg + 3.0 mg · kg-1 · h-1 (n = 5 per group). The lowest dose was ineffective, as a high degree of clot formation (314 ± 160 mg) occurred as determined by quantitation of protein deposits in the pump line filter. The three higher doses inhibited clot formation (35 to 44 mg) but did not reveal a dose-dependent effect (p = 0.308 between groups). All four doses produced the same amount of postoperative blood loss (6.5 to 10 g/kg over 2 hours; p = 0.215 between groups) and no oozing of blood from cut tissues (sternum, muscle, skin) during or after operation. No adverse hemodynamic or hematologie effeds were observed. Animals were physiologically stable coming off pump, requiring minimal fluid replacement or other cardiovascular supportive measures. The chromogenic anti-lla assay could be used to monitor CGP 39393. Same activated partial thromboplastin time and all activated clotting time values were off scale on pump, but they fell immediately after cardiopulmonary bypass, typicalty reaching near-normal levels within 30 to 60 minutes. No reversal of CGP 39393 was used, as blood levels declined rapidly after cessation of the infusion. This stady in 2 dog model shows that CGP 39393 administered as a bolus plus infusion (minimum dose, 1.0 mg/kg + 1.50 mg · kg-1 · h-1) can be used safely and effectively during cardiopulmonary bypass for cardiac operation.",
author = "Walenga, {Jeanine M.} and Koza, {Michael J.} and Park, {Soon J.} and Terrell, {Mark R.} and Roque Pifarr{\'e}",
year = "1994",
doi = "10.1016/0003-4975(94)91661-6",
language = "English (US)",
volume = "58",
pages = "1685--1689",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model

AU - Walenga, Jeanine M.

AU - Koza, Michael J.

AU - Park, Soon J.

AU - Terrell, Mark R.

AU - Pifarré, Roque

PY - 1994

Y1 - 1994

N2 - Recombinant desulphatohirudin HV1 (CGP 39393), a specific and potent peptidic inhibitor of thrombin, was evaluated as the sole anticoagulant in a dog model of cardiopulmonary bypass. CGP 39393 was administered as a bolus plus infusion for a 1-hour pump period at doses of 1.0 mg/kg + 0.75 mg·kg-1.h-1, 1.0 mg/kg + 1.50 mg · kg-1 · h-1, 1.0 mg/kg + 225 mg · kg-1 · h-1, or 1.0 mg/kg + 3.0 mg · kg-1 · h-1 (n = 5 per group). The lowest dose was ineffective, as a high degree of clot formation (314 ± 160 mg) occurred as determined by quantitation of protein deposits in the pump line filter. The three higher doses inhibited clot formation (35 to 44 mg) but did not reveal a dose-dependent effect (p = 0.308 between groups). All four doses produced the same amount of postoperative blood loss (6.5 to 10 g/kg over 2 hours; p = 0.215 between groups) and no oozing of blood from cut tissues (sternum, muscle, skin) during or after operation. No adverse hemodynamic or hematologie effeds were observed. Animals were physiologically stable coming off pump, requiring minimal fluid replacement or other cardiovascular supportive measures. The chromogenic anti-lla assay could be used to monitor CGP 39393. Same activated partial thromboplastin time and all activated clotting time values were off scale on pump, but they fell immediately after cardiopulmonary bypass, typicalty reaching near-normal levels within 30 to 60 minutes. No reversal of CGP 39393 was used, as blood levels declined rapidly after cessation of the infusion. This stady in 2 dog model shows that CGP 39393 administered as a bolus plus infusion (minimum dose, 1.0 mg/kg + 1.50 mg · kg-1 · h-1) can be used safely and effectively during cardiopulmonary bypass for cardiac operation.

AB - Recombinant desulphatohirudin HV1 (CGP 39393), a specific and potent peptidic inhibitor of thrombin, was evaluated as the sole anticoagulant in a dog model of cardiopulmonary bypass. CGP 39393 was administered as a bolus plus infusion for a 1-hour pump period at doses of 1.0 mg/kg + 0.75 mg·kg-1.h-1, 1.0 mg/kg + 1.50 mg · kg-1 · h-1, 1.0 mg/kg + 225 mg · kg-1 · h-1, or 1.0 mg/kg + 3.0 mg · kg-1 · h-1 (n = 5 per group). The lowest dose was ineffective, as a high degree of clot formation (314 ± 160 mg) occurred as determined by quantitation of protein deposits in the pump line filter. The three higher doses inhibited clot formation (35 to 44 mg) but did not reveal a dose-dependent effect (p = 0.308 between groups). All four doses produced the same amount of postoperative blood loss (6.5 to 10 g/kg over 2 hours; p = 0.215 between groups) and no oozing of blood from cut tissues (sternum, muscle, skin) during or after operation. No adverse hemodynamic or hematologie effeds were observed. Animals were physiologically stable coming off pump, requiring minimal fluid replacement or other cardiovascular supportive measures. The chromogenic anti-lla assay could be used to monitor CGP 39393. Same activated partial thromboplastin time and all activated clotting time values were off scale on pump, but they fell immediately after cardiopulmonary bypass, typicalty reaching near-normal levels within 30 to 60 minutes. No reversal of CGP 39393 was used, as blood levels declined rapidly after cessation of the infusion. This stady in 2 dog model shows that CGP 39393 administered as a bolus plus infusion (minimum dose, 1.0 mg/kg + 1.50 mg · kg-1 · h-1) can be used safely and effectively during cardiopulmonary bypass for cardiac operation.

UR - http://www.scopus.com/inward/record.url?scp=0027973347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027973347&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(94)91661-6

DO - 10.1016/0003-4975(94)91661-6

M3 - Article

C2 - 7979736

AN - SCOPUS:0027973347

VL - 58

SP - 1685

EP - 1689

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -